Evidence map›Paper›PMID 17471238›Full record

ReviewOncogene2007

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

M M Moasser

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01730118 (A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression), which is not on this map. Cited by 628 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
628citing papers in PubMed, 1 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01730118 phase1completednot on this mapstarted 2013, after this paper: background citation

A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2013 to 2019Enrolled33ConditionsBreast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu ExpressionArmsAdenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
3 · Its place in the literature

Who cites it

628 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,204 citations in OpenAlex.

  1. HER2 discordance between primary and metastatic gastric cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. [Expression characteristics and clinical significance ofBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

568 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

M M MoasserDepartment of Medicine and Comprehensive Cancer Center, University of California, San Francisco, CA 94143-0875, USA. mmoasser@medicine.ucsf.edu
UCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Understanding resistance to HER family tyrosine kinase inhibitorsR01CA122216 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOASSER, MARK M · 2007 to 2017
$3.0M
NCI NIH HHS R01 CA122216
6 · The paper itself

Abstract

The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer. This finding established the HER2 oncogene hypothesis for the development of some human cancers. The subsequent two decades have brought about an explosion of information about the biology of HER2 and the HER family. An abundance of experimental evidence now solidly supports the HER2 oncogene hypothesis and etiologically links amplification of the HER2 gene locus with human cancer pathogenesis. The molecular mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged. Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by experimental models and HER2 may indeed induce cell transformation through multiple mechanisms. Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the experimental evidence with human cancer pathogenesis.

Indexed as

Cell Transformation, NeoplasticSignal TransductionAnimalsErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticGenes, erbB-2HumansMiceModels, BiologicalMutationNeoplasmsErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID17471238
PMCPMC3021475
OpenAlexW2056579307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.